For the millions of people who track their steps or heart rate, the path to a basic health metric runs through a wearable device, a pharmacy kiosk, or a doctor’s appointment. AIME Scan, a new app from a small team in South Carolina, proposes a different route: a one-minute scan using only a smartphone’s front-facing camera [aimescan.com, retrieved 2024]. The company’s bet is that software alone, powered by AI and deep learning models, can make checking key wellness indicators as effortless as opening an app [aimescan.com, retrieved 2024].
The software-only wedge
AIME’s core proposition is its lack of hardware. It uses the smartphone camera to capture physiological signals through the skin, which are then processed by proprietary algorithms [aimescan.com, retrieved 2024]. The company claims the technology can measure heart rate, blood oxygen levels, and stress in under 60 seconds. More ambitiously, its website states the scan can also assess A1C levels and evaluate an individual’s risk for hypertension, diabetes, and high cholesterol [aimescan.com, retrieved 2024].
A quiet and cautious launch
Operating under the legal entity CCAM LLC, AIME Scan presents a notably low-profile footprint for a digital health venture [Perplexity Sonar Pro, retrieved 2024]. Founded in 2024 and headquartered in Simpsonville, South Carolina, the company lists a team size of just 2-10 employees [LinkedIn, retrieved 2024]. No founders or executives are named on its website or LinkedIn profile, and there is no public record of institutional funding. The app is live on both the Apple App Store and Google Play, where a note indicates users must register a membership on the company’s website to activate the health scan features [Perplexity Sonar Pro, retrieved 2024].
The validation gap
The ambition to democratize health screening is clear, but the absence of external scientific validation is the central, looming question. Measuring complex biomarkers like A1C or cholesterol risk via a smartphone camera represents a significant technical leap beyond photoplethysmography (PPG) for heart rate. Without FDA clearance, CE marking, or published clinical studies, these claims remain marketing assertions. The regulatory pathway for such software-as-a-medical-device (SaMD) is rigorous for a reason: patient safety. For AIME to move from a wellness curiosity to a trusted tool, it must eventually navigate this process.